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o r i g i n a l a r t i c l e
Effectiveness of Measures to Eradicate Staphylococcus aureus
Carriage in Patients with Community-Associated Skin and
Soft-Tissue Infections: A Randomized Trial
Stephanie A. Fritz, MD, MSCI;1,a Bernard C. Camins, MD, MSCR;2,a Kimberly A. Eisenstein, BS;1,2 Joseph M. Fritz, MD;2
Emma K. Epplin, BS;1,2 Carey-Ann Burnham, PhD;1,3 Jonathan Dukes, MPH;2 Gregory A. Storch, MD1,2
background. Despite a paucity of evidence, decolonization measures are prescribed for outpatients with recurrent Staphylococcus aureus
skin and soft-tissue infection (SSTI).
objective. Compare the effectiveness of 4 regimens for eradicating S. aureus carriage.
design. Open-label, randomized controlled trial. Colonization status and recurrent SSTI were ascertained at 1 and 4 months.
setting. Barnes-Jewish and St. Louis Children’s Hospitals, St. Louis, Missouri, 2007–2009.
participants. Three hundred patients with community-onset SSTI and S. aureus colonization in the nares, axilla, or inguinal folds.
interventions. Participants were randomized to receive no therapeutic intervention (control subjects) or one of three 5-day regimens:
2% mupirocin ointment applied to the nares twice daily, intranasal mupirocin plus daily 4% chlorhexidine body washes, or intranasal
mupirocin plus daily dilute bleach water baths.
results. Among 244 participants with 1-month colonization data, modified intention-to-treat analysis revealed S. aureus eradication
in 38% of participants in the education only (control) group, 56% of those in the mupirocin group ( vs controls), 55% of thosePp .03
in the mupirocin and chlorhexidine group ( ), and 63% off those in the mupirocin and bleach group ( ). Of 229 participantsPp .05 Pp .006
with 4-month colonization data, eradication rates were 48% in the control group, 56% in the mupirocin only group ( vs controls),Pp .40
54% in the mupirocin and chlorhexidine group ( ), and 71% in the mupirocin and bleach group ( ). At 1 and 4 months,Pp .51 Pp .02
recurrent SSTIs were reported by 20% and 36% of participants, respectively.
conclusions. An inexpensive regimen of dilute bleach baths, intranasal mupirocin, and hygiene education effectively eradicated S.
aureus over a 4-month period. High rates of recurrent SSTI suggest that factors other than endogenous colonization are important
determinants of infection.
trial registration. ClinicalTrials.gov identifier: NCT00513799.
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Over the past decade, the incidence of staphylococcal skin and
soft-tissue infections (SSTIs) has increased significantly.1-3
Staphylococcus aureus colonization is a demonstrated risk fac-
tor for the development of SSTI.4-6 Measures to eradicate S.
aureus carriage, including intranasal mupirocin and bathing
with chlorhexidine antiseptic, have been evaluated in the pre-
vention of nosocomial infections. The effectiveness of these
measures has varied across different studies and has been
shown to wane over extended periods of time.7-11
The recent increase in the incidence of SSTI in otherwise
healthy individuals is largely attributable to a virulent,
community-associated (CA) methicillin-resistant S. aureus
(MRSA) clone designated USA300.12 When this clone first
emerged, it represented the majority of CA-MRSA isolates.
More recently, similarly virulent strains of methicillin-
susceptible S. aureus (MSSA) have also been shown by means
of genotyping to originate from USA300.2,13 Genomic se-
quencing of the USA300 clone suggests that these strains
possess novel gene content and altered regulation of virulence
determinants, which may enhance colonization and sur-
vival.14-16 Because of the distinct epidemiology, microbial
characteristics, and pathogenesis of contemporary CA S. au-
reus strains, eradication strategies employed in healthcare set-
tings may not be effective in preventing S. aureus transmission
randomized trial of ca s. aureus eradication 873
and infection in the community. The paucity of data available
to guide the prevention of recurrent S. aureus SSTI in com-
munity settings, as highlighted by recently published Infec-
tious Diseases Society of America MRSA clinical practice
guidelines, has engendered a wide variety of treatment and
decolonization practices.17,18 Traditional interventions, such
as mupirocin or chlorhexidine, are often prescribed,17,19 and
bathing in dilute bleach water has also been proposed,3 but
these measures have not been comprehensively evaluated with
a randomized trial in the outpatient setting.
The primary objective of this study was to investigate the
effectiveness of decolonization measures in eradicating S. au-
reus carriage from patients with SSTI in the community. The
secondary objectives were to determine rates of recurrent
SSTI among participants in the study arms and to evaluate
the acceptability of and adherence to these eradication mea-
sures by study participants. We hypothesized that a decolo-
nization regimen consisting of personal and household hy-
giene education and application of nasal mupirocin ointment
with either chlorhexidine body washes or dilute bleach water
baths would be twice as effective as hygiene education alone
in eradicating S. aureus colonization.
methods
Study Design
The St. Louis Staphylococcus aureus Reduction Study (StL
StaRS) was an open-label, randomized controlled trial at 2
hospitals that compared the effectiveness of 4 regimens to
eradicate S. aureus carriage from patients with CA-SSTI and
S. aureus colonization. This study was approved by the Wash-
ington University Human Research Protection Office.
Participants
Patients 6 months of age or older with acute, community-
onset SSTI were screened from the Emergency Department
(ED) and ambulatory wound center at St. Louis Children’s
Hospital (SLCH) and the Barnes-Jewish Hospital (BJH) ED.
At the time of screening, verbal informed consent, demo-
graphic information, and colonization swab samples (BBL
CultureSwab; Becton Dickinson) from the anterior nares, ax-
illa, and inguinal folds were obtained. Patients were excluded
if they had a postoperative wound infection, permanent in-
dwelling catheter, or percutaneous medical device; were preg-
nant or receiving dialysis; or resided in a long-term care fa-
cility. Patients colonized with S. aureus (MRSA or MSSA) at
one or more of the sampled sites were eligible for enrollment.
Study Intervention and Randomization
Enrollment was conducted in the Clinical Research Center
(CRC) at SLCH or BJH from April 2007 through May 2009
after the patient’s acute SSTI had healed. The median time
from screening to enrollment was 16.5 days (interquartile
range, 15.0 days) and did not differ significantly between
treatment arms (Table 1). Written informed consent and as-
sent, when applicable, were obtained at enrollment. Random-
ization was conducted by B.C.C. with an Internet-based,
computer-generated randomization schedule using permuta-
tion blocks of 8. The designated intervention for each partic-
ipant was sealed inside a numbered security envelope by S.A.F.
and was opened at the enrollment visit by a research coordi-
nator. Participants were randomized to receive 1 of 4 inter-
ventions:
1. Personal and household hygiene education only. This
included instructions to discard lotions in jars and replace
them with pump or pour bottles; refrain from sharing per-
sonal hygiene items (eg, hairbrushes, razors, or towels); wash
(in hot water) bed linens at least once weekly and towels and
washcloths after each use.
2. Education plus application of 2% mupirocin ointment
to the bilateral anterior nares twice daily for 5 days.
3. Education and intranasal 2% mupirocin ointment in
addition to daily body washes with 4% chlorhexidine solution
(Hibiclens; Mo¨lnlycke Health Care), used as a liquid soap,
for 5 days.
4. Education and intranasal 2% mupirocin ointment in
addition to daily 15-minute soaks in dilute bleach water (a
quarter cup of 6% sodium hypochlorite [Clorox; Clorox
Company] per tub of water) for 5 days.
Oral and written instructions and diagrams were provided
to study participants. Intranasal application of mupirocin
ointment using a sterile cotton applicator was demonstrated
by the study staff. Participants or parents were then required
to demonstrate the mupirocin application procedure to con-
firm their understanding. All study materials were supplied
to the participants. For participants randomized to the bleach
bath arm, a measuring cup marked at one-fourth cup was
provided. Decolonization measures were completed by par-
ticipants at home.
Data Collection at Baseline and Follow-Up
At enrollment, a questionnaire was administered to each par-
ticipant to collect information regarding medical history, hy-
giene practices, household factors, employment, and other
activities (factors listed in Table 1). Upon completion of the
5-day decolonization protocol, each participant was contacted
by telephone to assess their adherence to the protocol, adverse
reactions, and ease of performing each protocol step.
Participants were followed up longitudinally, with follow-
up visits 1 and 4 months after randomization at the SLCH
or BJH CRC. At each follow-up visit, participants had samples
collected to detect S. aureus colonization in the anterior nares,
axilla, and inguinal folds. A survey was administered to as-
certain interval SSTI in the participant or a household mem-
ber. Study participation concluded with a telephone call 6
months after enrollment to ascertain SSTI recurrence; all
follow-up was completed by November 2009. Twelve partic-
ipants were unable to return for follow-up visits because of














Age, mean years (SD) 17.37  16.57 16.52  16.12 18.19  17.37 18.67  15.29 .92
Male sex 41 (55) 38 (51) 23 (31) 37 (49) .02
Nonwhite race 56 (75) 48 (64) 57 (76) 52 (69) .35
Health insurance status .72
Private 22 (29) 26 (35) 23 (31) 29 (39)
Public 40 (53) 41 (55) 38 (51) 33 (45)
None 13 (17) 8 (11) 13 (18) 12 (16)
Colonization
MRSA only 42 (56) 39 (52) 44 (59) 50 (67) .31
MSSA only 25 (33) 28 (37) 23 (31) 20 (27) .56
Both MRSA and MSSA 8 (11) 8 (11) 8 (11) 5 (7) .79
Baseline sites of colonizationa
Anterior nares 52 (69) 51 (68) 49 (65) 54 (72) .85
Axilla 19 (25) 27 (36) 22 (29) 23 (31) .56
Inguinal folds 58 (77) 50 (67) 59 (79) 56 (75) .33
Baseline no. of sites colonized
1 site 35 (47) 33 (44) 34 (45) 33 (44) .98
2 sites 26 (35) 31 (41) 27 (36) 26 (35) .81
3 sites 14 (19) 11 (15) 14 (19) 16 (21) .77
Prescribed systemic antibiotic(s) at
time of acute SSTI
64 (85) 68 (91) 69 (92) 68 (91) .55
Colonized and/or infected with a
mupirocin-resistant S. aureus
strain
3 (4) 1 (1) 1 (1) 1 (1) .56
Time from screening to enrollment,
median days (IQR)
17 (15) 17 (15) 16 (13) 16 (15) .93
Comorbidity
Any 49 (65) 46 (61) 50 (67) 48 (64) .92
Asthma 26 (35) 14 (19) 13 (17) 16 (21) .04
Eczema 28 (37) 15 (20) 32 (43) 19 (25) .01
Allergies 10 (13) 13 (17) 17 (23) 24 (32) .03
Hypertension 5 (7) 4 (5) 9 (12) 7 (9) .46
HIV infection 0 (0) 0 (0) 4 (5) 0 (0) .01
Takes a prescription medication daily 30 (40) 24 (32) 23 (32) 31 (41) .43
Has taken antibiotics within past
year
40 (54) 42 (58) 45 (65) 41 (56) .59
Surgery within past year 5 (7) 6 (8) 14 (19) 6 (8) .05
Emergency department or urgent
care visit within past year
30 (40) 27 (36) 27 (36) 36 (48) .39
Contact with healthcareb 20 (27) 21 (28) 18 (24) 20 (27) .95
Prior SSTI within past year
Index case 31 (42) 36 (48) 36 (49) 40 (53) .58
Household member 33 (45) 27 (36) 35 (47) 24 (32) .24
Permanent home 65 (87) 69 (92) 68 (91) 67 (89) .74
Crowded home (12 people per
bedroom)
7 (9) 8 (11) 7 (9) 13 (17) .36
Sports participation 19 (25) 18 (24) 11 (15) 18 (24) .36
Pet in household 28 (37) 29 (39) 26 (35) 26 (35) .94
note. Data are no. (%) of participants, unless otherwise indicated. P values are for comparisons across all 4 randomization groups.
HIV, human immunodeficiency virus; IQR, interquartile range; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-sensitive S.
aureus; SD, standard deviation; SSTI, skin or soft-tissue infection.
a Participants may have been colonized at more than 1 body site.
b Participant works in a healthcare facility or lives with someone who works in a healthcare facility.
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figure 1. Flow of participants through the St. Louis Staphylococcus aureus Reduction Study trial.
geographic location. For these participants, the survey was
conducted by telephone, and swabs were delivered to the
participant’s home accompanied by a diagram and detailed
instructions for obtaining and returning the culture swab
samples (validated by our group and others20,21).
Study Outcomes
The primary outcome measure was eradication of S. aureus
carriage 1 month after intervention. Eradication was defined
as the absence of S. aureus carriage at the 3 sampled body
sites. Secondary outcomes included S. aureus eradication at
4 months; recurrent SSTI at 1, 4, and 6 months; and ac-
ceptability of and adherence to the intervention methods.
Laboratory Methods
Swab samples were incubated overnight in tryptic soy broth
with 6.5% NaCl (BBL; Becton Dickinson) at 35C. A sample
of broth was plated to trypticase soy agar with 5% sheep
blood (BBL; Becton Dickinson) and incubated overnight. S.
aureus isolates were identified and antibiotic susceptibility
testing was performed according Clinical and Laboratory
Standards Institute procedures as previously described.22,23
Laboratory personnel were blinded to randomization assign-
ments. Follow-up swab samples collected by participants at
home all yielded normal flora, which suggested that swab
samples were indeed representative of the designated body
sites.
Real-time polymerase chain reaction was performed for all
recovered S. aureus isolates, using established primers, to
detect the mupA gene encoding high-level mupirocin
resistance.24
Statistical Analysis
Based on published data,5 we anticipated 50% eradication of
S. aureus carriage in the control group, who received only
hygiene education. Based on this assumption, 57 participants
per group were needed to detect a 50% relative reduction in
S. aureus colonization at 1 month ( and study powerap 0.05
at 80%) when comparing each intervention group with the
control group. To account for a possible 25% attrition, we
enrolled 75 participants in each arm (300 total participants).
Demographic and baseline characteristics were evaluated
with descriptive statistics. Outcomes were determined by
modified intention-to-treat analysis, including participants
who attended longitudinal visits. Statistical analyses were per-
formed using SPSS for Windows, version 17.0 (SPSS) unless
otherwise specified. Pearson’s x2 analyses and analysis of var-
iance (or Kruskal-Wallis test where appropriate) were per-
formed to compare characteristics among participants in the
4 study arms. Statistical significance values for relative risk
(RR) and absolute risk reduction (ARR) for S. aureus erad-
ication and recurrent SSTI between the control group and
the intervention arms were determined by Pearson’s x2.
Fisher’s exact tests were performed using R (R Foundation)
in cases of small cell sizes. Potential confounding baseline
characteristics that differed significantly between arms (P ≤
) were evaluated with binary logistic regression. All tests for.05
significance were 2-sided, and P values of ≤.05 were considered
statistically significant. The RR was considered to be significant
if the 95% confidence interval (CI) did not include 1.
results
Baseline Patient Characteristics
Of 782 patients with acute SSTI assessed for eligibility, 300
were enrolled in the trial. Participants were randomly allo-
cated to 4 intervention groups of 75 participants each (Figure
1). Overall, 193 children (64%) and 107 adults (36%) were
enrolled. The treatment groups were similarly distributed at
baseline with the exception of sex, several comorbidities
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(asthma, eczema, allergies, and human immunodeficiency vi-
rus infection), and surgery within the past year (Table 1).
These factors did not influence the relationship between treat-
ment group and outcomes (data not shown).
Primary and Secondary Outcomes
S. aureus eradication at 1 month. The 1-month colonization
evaluation was completed by 244 participants. Modified in-
tention-to-treat analysis revealed significantly greater S. au-
reus eradication with each of the 3 decolonization regimens,
compared with the control group, which received only per-
sonal and household hygiene education. S. aureus eradication
occurred in 38% of control subjects. Compared with control
subjects, eradication was achieved for 56% of participants
who were randomized to education plus mupirocin (Pp
vs control subjects); 55% of those who were randomized.03
to education, mupirocin, and chlorhexidine ( ); andPp .05
63% of those who were randomized to education, mupirocin,
and bleach baths ( ; Table 2).Pp .006
S. aureus eradication at 4 months. Colonization data were
available for 229 participants at 4 months. S. aureus was erad-
icated from 48% of control subjects. Compared with control
subjects, eradication was achieved in 56% of participants in
the education plus mupirocin group ( ); 54% in thePp .40
education, mupirocin, and chlorhexidine group ( );Pp .51
and 71% in the education, mupirocin, and bleach baths group
( ; Table 2).Pp .02
Body site–specific eradication. Colonization of the nares
was significantly reduced at 1 and 4 months in all participants
who received mupirocin, compared with control subjects. In
addition, inguinal colonization was significantly lower at 1
month in participants who were randomized to bleach baths,
compared with those who did not perform bleach baths (Ta-
ble 3).
Rates of recurrent SSTI. Recurrent SSTI was reported by
20% of participants at 1 month, 36% at 4 months, and 49%
at 6 months. There were significantly fewer reports of re-
current SSTI at 1 month by participants who received edu-
cation, mupirocin, and chlorhexidine (11%) than by control
subjects (26%; ; all other differences were not sig-Pp .03
nificant; Table 4).
Protocol acceptability and adherence. No serious adverse
events were reported. Of 283 participants who provided in-
formation, 39 reported adverse effects. The most common
reactions included dry skin (in 21 [7%] of the participants),
rash (9 [3%]), and rhinorrhea or nasal irritation (4 [1%]).
A greater number of reactions were experienced by partici-
pants who performed chlorhexidine body washes (20%) and
bleach baths (25%) than by control subjects (6%; Pp .01
and , respectively). Mupirocin, chlorhexidinePp .001
washes, and bleach baths were reportedly easy to perform for
84% (174 of 208), 82% (56 of 68), and 77% (51 of 66) of
the participants, respectively. Of those with follow-up infor-
mation, adherence to protocol assignment was reported by
72% of control subjects; 64% of participants in the education
and mupirocin group; 70% of participants in the education,
mupirocin, and chlorhexidine group; and 62% of participants
in the education, mupirocin, and bleach baths group. In
groups assigned to multiple interventions, adherence to hy-
giene measures was consistently lower than was adherence to
topical treatments (Table 5).
discussion
This is, to our knowledge, the first study to compare the
effectiveness of multiple approaches for S. aureus eradication
from multiple body sites in the community. Decolonization
regimens employing intranasal mupirocin alone and in com-
bination with chlorhexidine body washes or dilute bleach
baths were effective in S. aureus eradication 1 month after
the intervention, compared with personal and household hy-
giene education alone. Interestingly, only the regimen that
combined hygiene education, intranasal mupirocin, and
bleach baths achieved a statistically significant reduction in
S. aureus colonization rates at 4 months.
The findings of this study are encouraging, because bleach
is readily available and very affordable (approximately 40
cents per 5-day course of daily baths, compared with $10 per
8 fluid ounces of chlorhexidine). Bleach, or sodium hypo-
chlorite, has S. aureus antimicrobial activity both in vivo and
in vitro and has been used by dermatologists to treat eczema,
presumably by suppressing S. aureus growth.25-28 Variable di-
lutions of bleach added to bathwater have been recom-
mended.3,25,27,28 In this study, we asked participants to add
one-quarter cup of bleach to a bathtub full of water. Although
this presumably resulted in a range of dilutions among study
participants, we wanted to make the intervention easy and
practical. Considering typical bathtub sizes and volumes of
water used,27 we estimate that most bleach bath participants
were exposed to sodium hypochlorite concentrations of
0.002%–0.009%. We believe that soaking in dilute bleach wa-
ter provided the most exposure for all body parts, especially
the inguinal folds, and that longer contact with bleach may
have provided a greater antimicrobial effect. In fact, inguinal
colonization was significantly reduced in patients in the
bleach group, compared with those in the chlorhexidine
group. In contrast, chlorhexidine was applied as liquid soap
and rinsed off. Used in this manner, chlorhexidine likely pro-
vided little residual antimicrobial activity and may have had
less contact with the inguinal area, which is a frequently col-
onized body site.29 The use of chlorhexidine-impregnated
cloths, in which chlorhexidine is not rinsed from the skin,
may be more effective in S. aureus eradication. These cloths
have been effective in preventing hospital-acquired infections
in intensive care unit settings.30,31
Regardless of the setting (healthcare or community), agree-
ment has not been reached regarding the optimal approach
to S. aureus decolonization. Numerous decolonization stud-
ies, evaluating a variety of regimens, have been conducted in
randomized trial of ca s. aureus eradication 877









and bleach baths P
One month after intervention
Eradication 24/64 (38) 35/62 (56) .03 35/64 (55) .05 34/54 (63) .006
RR (95% CI) ... 1.51 (1.02–2.21) 1.46 (0.99–2.15) 1.68 (1.15–2.44)
ARR (95% CI) ... 19 (2–35) 18 (1–34) 24 (6–40)
Four months after intervention
Eradication 31/64 (48) 32/57 (56) .40 31/57 (54) .51 36/51 (71) .02
RR (95% CI) ... 1.16 (0.82–1.63) 1.12 (0.79–1.58) 1.46 (1.07–1.98)
ARR (95% CI) ... 8 (10 to 25) 7 (11 to 24) 21 (3–37)
note. Data are proportion (%) of participants, unless otherwise indicated. The hygiene education only (control) group was used as the
comparator group to determine relative risk (RR), absolute risk reduction (ARR), and P values. P value represents comparison between
the intervention group and the control group. Participants were analyzed by the arm to which they were assigned. CI, confidence interval.









and bleach baths P
Nasal colonizationa
At 1 month 24/52 (46) 14/51 (27) .049 13/49 (26) .041 9/54 (17) .001
At 4 months 26/52 (50) 12/51 (23) .005 12/49 (24) .008 8/54 (15) !.001
Axilla colonization
At 1 month 5/19 (26) 6/27 (22) NS 4/22 (18) NS 2/23 (9) NS
At 4 months 4/19 (21) 4/27 (15) NS 3/22 (14) NS 2/23 (9) NS
Inguinal colonizationb
At 1 month 23/58 (40) 16/50 (32) NS 19/59 (32) NS 8/56 (14) .002
At 4 months 15/58 (26) 12/50 (24) NS 18/59 (30) NS 9/56 (16) NS
note. Data are proportion (%) of participants, unless otherwise indicated. P values shown are versus the hygiene education only (control)
group, unless otherwise noted. NS, not significant.
a All participants randomized to receive mupirocin vs control subjects: at 1 month, at 4 months.Pp .002 P ! .001
b Participants randomized to bleach bath group vs all others: at 1 month, at 4 months. Participants randomized toPp .004 Pp .10
bleach bath group vs participants randomized to chlorhexidine group: at 1 month, at 4 months.Pp .02 Pp .07
healthcare settings to prevent nosocomial infections, with
varying results.7-11,32,33 For example, a meta-analysis of topical
and systemic antimicrobials by Ammerlaan et al32 concluded
that short-term application of nasal mupirocin was highly
effective for eradicating MRSA carriage and achieved a 90%
success rate 1 week after treatment. However, other meta-
analyses have focused on the nondurability of such beneficial
effects and have concluded that there is insufficient evidence
for the use of topical or systemic therapies for S. aureus erad-
ication.7,33As in decolonization studies conducted in health-
care settings,7-9 we found that CA S. aureus eradication
achieved at 1 month by the application of mupirocin alone
or in combination with chlorhexidine washes was not sus-
tained. Thus, an effective regimen for long-term S. aureus
eradication remains unclear.
S. aureus colonization at sites other than the anterior nares,
including the groin, axilla, and pharynx, has been identified
by our group and others as reservoirs for a high burden of
S. aureus carriage.29,34,35 In accordance with this, the reported
efficacy of intranasal mupirocin ointment is lower in studies
that evaluate multiple body sites for colonization than in
those that assess colonization of the nares alone.32 Thus, an
approach that includes decolonization of extra-nasal sites of
S. aureus carriage may be critical to prevent transmission and
infection. Because of the relatively low cost of bleach, and
because resistance to mupirocin can develop with widespread
use,36,37 a prolonged decolonization approach aimed at sus-
tained eradication and consisting of dilute bleach baths with-
out the use of intranasal mupirocin warrants further study.
Orally administered antibiotics achieve short-term MRSA
eradication rates approaching 60%, but antimicrobial resis-
tance develops more commonly with regimens that include
systemic antibiotics.32
Despite the effectiveness of the studied interventions in
reducing S. aureus colonization, participants in all study arms
experienced a substantial rate of recurrent SSTI. In our co-
hort, 20% of participants reported recurrent SSTI within a
month of study enrollment, which is consistent with other
longitudinal studies.38,39 Similarly, in a study involving MRSA-
colonized soldiers conducted by Ellis et al,40 although appli-
cation of mupirocin to the anterior nares successfully erad-
icated nasal carriage in the treated soldiers, it did not decrease
infection rates in these soldiers or their peers. Because erad-
ication of endogenous colonization alone does not eliminate
878 infection control and hospital epidemiology september 2011, vol. 32, no. 9









and bleach baths P
One month after intervention
SSTI reported 17/65 (26) 14/62 (23) .64 7/63 (11) .03 12/55 (22) .58
RR (95% CI) ... 0.86 (0.47–1.60) 0.42 (0.19–0.95) 0.83 (0.44–1.59)
ARR (95% CI) ... 4 (10 to 2) 15 (3-28) 4 (10 to 19)
Four months after intervention
SSTI reported 26/64 (41) 20/59 (34) .44 19/57 (33) .41 18/52 (35) .51
RR (95% CI) ... 0.83 (0.52–1.33) 0.82 (0.51–1.32) 0.85 (0.53–1.37)
ARR (95% CI) ... 7 (10 to 23) 7 (10 to 24) 6 (11 to 23)
Six months after intervention
SSTI reported 28/52 (54) 27/52 (52) .84 23/54 (43) .25 21/43 (50) .63
RR (95% CI) ... 0.96 (0.67–1.39) 0.79 (0.53–1.17) 0.91 (0.61–1.35)
ARR (95% CI) ... 2 (17 to 20) 11 (8 to 29) 5 (15 to 24)
note. Data are proportion (%) of participants, unless otherwise indicated. The hygiene education only (control) group was used as the
comparator group to determine relative risk (RR), absolute risk reduction (ARR), and P values. P value represents comparison between
the intervention group and the control group. Participants were analyzed by the arm to which they were assigned. CI, confidence interval;
SSTI, skin or soft-tissue infection.










Hygiene measures 52/72 (72) 50/72 (69) 55/71 (78) 46/68 (68)
Intranasal mupirocin ... 68/72 (94) 68/71 (96) 65/68 (96)
Chlorhexidine ... ... 63/70 (90) ...
Bleach baths ... ... ... 66/68 (97)
All assigned measures 52/72 (72) 46/72 (64) 49/70 (70) 42/68 (62)
note. Data are proportion (%) of participants. There was not a statistically significant difference in compliance
with the assigned regimens between participants in the 4 randomization arms. Adherence for each protocol com-
ponent was defined as completion of 3 hygiene steps (discarding lotions in jars, not sharing personal hygiene items,
and washing bed linens and towels in hot water), mupirocin application twice daily for 5 days, chlorhexidine body
washes daily for 5 days, and bleach baths daily for 5 days.
subsequent infection, an improved understanding of other
determinants of CA S. aureus pathogenesis, including envi-
ronmental factors and person-to-person transmission, is
needed.
There are several limitations to this study. For logistical
reasons, this randomized trial was conducted as an open trial,
rather than as a blinded, placebo-controlled trial. Given the
objective primary outcome (S. aureus eradication as deter-
mined by culture), we do not believe the lack of blinding
introduced significant bias into the results. Although we did
not directly monitor adherence to the measures, 67% of the
participants reported adherence with assigned decolonization
measures, and reported rates of compliance with therapeutic
interventions (mupirocin, chlorhexidine, and bleach) were
very high (190%). In addition, because of the pain and in-
convenience of recurrent SSTI, we believe that many patients
were motivated to complete the decolonization measures in
an attempt to prevent future infection. Household members
were not included in this trial and were not asked to perform
the decolonization measures. CA S. aureus infections have
been observed to cluster within households,41 and study par-
ticipants may have reacquired the organism from close house-
hold contacts. We are conducting a separate trial to compare
the effectiveness of decolonization interventions directed at
all household members with that of interventions directed at
the index patient alone. Lastly, the incidence of recurrent SSTI
was determined by patient report. We feel this was a valid
measure given that each participant had experienced at least
one prior SSTI (at the time of screening).
In summary, a regimen of dilute bleach water baths, in-
tranasal mupirocin, and personal and household hygiene ed-
ucation was effective for S. aureus eradication in the out-
patient setting for individuals with CA-SSTI. Although our
results may be generalizable to other diverse populations of
children and adults colonized with contemporary S. aureus
strains, additional studies are needed to evaluate prolonged
or intermittent decolonization approaches. Larger multicen-
ter trials evaluating the efficacy and cost-effectiveness of these
measures in reducing the morbidity of recurrent SSTI in in-
dividuals and communities will be vital to improving the lives
of patients who are affected by CA S. aureus.
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